Clinical Trial Update: Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating busulfan-based conditioning with h-ATG, radiation, and sirolimus for matched related/unrelated donor stem cell transplanta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Immunodeficiency

Drugs mentioned

• BUSULFAN (Busulfan)
• Horse anti-thymocyte globulin (anti-thymocyte globulin (equine))
• Sirolimus (Sirolimus)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Severe Combined Immune Deficiency (SCID) | Phase 1, Phase 2 | Status: WITHDRAWN